Streetwise Reports' Article Archives — April 2022 back to current month (23)

Is Reliq Health Technologies a Nutrimental 'Buy'? (04/29/2022)

After recovering from a short "character assassination," Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good 'buy'.

more>

Could a New Prescription Drug Treat This Common Ailment? (04/27/2022)

The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.

more>

Biopharma Co. Posts 32% YoY Gain in Proprietary Sales (04/27/2022)

Alkermes Plc. shares traded 12% higher after the Ireland-based company reported Q1/22 financial results and reiterated its FY/22 business outlook.

more>

Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials (04/25/2022)

Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies.

more>

FDA Grants RMAT Status for T-Cell Therapy for Six Viruses (04/20/2022)

Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients.

more>

Senior Biotech Analyst's Top 3 Stocks (04/19/2022)

Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs.

more>

Biotech Co.'s Shares Quadruple on $250M Buyout Bid (04/19/2022)

Shares of Checkmate Pharmaceuticals Inc. traded 330% higher to a new 52-week high after the company reported it agreed to be acquired by Regeneron Pharmaceuticals Inc. for $10.50 per share in cash.

more>

Life Sciences Co. Expected to Attract Partners, Big Pharma (04/19/2022)

"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases.

more>

EU PE Firm Makes $1.2B Bid for US Medical Device Co. (04/18/2022)

Shares of Natus Medical Inc. traded 29% higher after the company reported it agreed to be acquired by ArchiMed Group, a France-based private equity firm, for $33.50 per share in cash.

more>

Vaccine Maker Awarded Approval for COVID-19 Vaccine (04/14/2022)

Shares of Valneva SE traded 8.5% higher after the company reported that the U.K.'s MHRA has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate called VLA2001 for primary immunization in adults between 18 and 50 years old.

more>

GSK Offers $1.9B for Cancer-Focused Pharma Co. (04/13/2022)

Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash.

more>

Cannabis Firm Increases YOY Revenue By 352% in 2021 (04/12/2022)

The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report.

more>

Biopharma Firm Signs $452M License Deal for BMT Drug (04/12/2022)

Shares of Actinium Pharmaceuticals Inc. traded 24% higher after the company reported it entered into a licensing and supply agreement for its antibody radiation conjugate, Iomab-B, with Sweden's Immedica Pharma AB for sales in Europe, the Middle East and North Africa.

more>

Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial (04/11/2022)

Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%.

more>

Co. Uses Protein Modulation to Treat Cancer (04/09/2022)

Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend.

more>

Surgical Device Maker's Shares Rise 7% on Q3 Earnings (04/07/2022)

Shares of AngioDynamics Inc. traded higher after the company reported Q3/22 financial results highlighting a 28.6% YoY increase in net Med Tech sales.

more>

FDA Approves Bipolar and Schizophrenia Drug (04/06/2022)

BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMI™ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

more>

Imaging Co. Launches S. Korea Chip Production (04/05/2022)

Shares of Nano-X Imaging Ltd. traded 9% higher after the company reported it opened a new semiconductor chip fabrication plant in South Korea. The 12,000 sq. meter facility was commissioned to produce the firm's Nanox.SOURCE semiconductor chips for its novel digital Nanox.ARC 3D x-ray system.

more>

Telemed Tech Co. Expands Markets and Revenue in 2022 (04/04/2022)

A quarter of the way into the year, this global healthcare technology company is experiencing “phenomenal growth,” with “a lot of growth ahead of us” for the rest of this year.

more>

Can We Make a Pill to End the Pandemic? (04/04/2022)

Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

more>

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase (04/04/2022)

Technical analyst Clive Maund explains why he rates this company a strong speculative buy.

more>

Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial (04/02/2022)

NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors.

more>

Chen's Top Picks for Q2 2022 (04/01/2022)

Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks.

more>

More Archives

2022Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes